Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Aug 6, 2026 | $1.03 | +33.8% | $2.18B | +4.8% | $2.01 |
| Q1 FY26ended Mar 31, 2026 | May 4, 2026 | $1.22 | +34.1% | $2.09B | +9.3% | $1.86 |
| Q4 FY25ended Dec 31, 2025 | — | $0.70 | −41.7% | $2.24B | +10.9% | — |
| Q3 FY25ended Sep 30, 2025 | — | $1.16 | −5.7% | $2.00B | +9.7% | — |
| Q2 FY25ended Jun 30, 2025 | — | $0.77 | −34.7% | $2.08B | +7.0% | — |
| Q1 FY25ended Mar 31, 2025 | — | $0.91 | +8.3% | $1.91B | +1.1% | — |
| Q4 FY24ended Dec 31, 2024 | — | $1.20 | −40.3% | $2.02B | +4.3% | — |
| Q3 FY24ended Sep 30, 2024 | — | $1.23 | +59.7% | $1.82B | +4.0% |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe Zimmer Biomet shares, not any token. As of Aug 6, 2026, from Massive's standardised financials and the earnings calendar.
| — |
| Q2 FY24ended Jun 30, 2024 | — | $1.18 | — | $1.94B | — | — |
| Q1 FY24ended Mar 31, 2024 | — | $0.84 | — | $1.89B | — | — |
| Q4 FY23ended Dec 31, 2023 | — | $2.01 | — | $1.94B | — | — |
| Q3 FY23ended Sep 30, 2023 | — | $0.77 | — | $1.75B | — | — |